GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 201 filers reported holding GENMAB A/S in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,350,982 | -37.6% | 38,304 | -33.2% | 0.00% | -20.0% |
| Q1 2023 | $2,163,988 | -11.9% | 57,309 | -1.1% | 0.01% | 0.0% |
| Q4 2022 | $2,455,158 | +8.3% | 57,932 | -17.9% | 0.01% | -16.7% |
| Q3 2022 | $2,268,000 | -5.3% | 70,579 | -4.3% | 0.01% | 0.0% |
| Q2 2022 | $2,396,000 | +10.4% | 73,746 | +22.9% | 0.01% | +20.0% |
| Q1 2022 | $2,170,000 | +1.2% | 59,988 | +10.6% | 0.01% | 0.0% |
| Q4 2021 | $2,145,000 | -8.4% | 54,230 | +1.2% | 0.01% | -16.7% |
| Q3 2021 | $2,341,000 | +12.1% | 53,575 | +4.7% | 0.01% | +20.0% |
| Q2 2021 | $2,089,000 | +46.7% | 51,154 | +17.9% | 0.01% | 0.0% |
| Q1 2021 | $1,424,000 | -23.5% | 43,372 | -5.2% | 0.01% | -16.7% |
| Q4 2020 | $1,861,000 | +24.1% | 45,763 | +11.7% | 0.01% | 0.0% |
| Q3 2020 | $1,499,000 | +254.4% | 40,953 | +228.3% | 0.01% | +200.0% |
| Q2 2020 | $423,000 | +43.9% | 12,473 | -10.1% | 0.00% | 0.0% |
| Q1 2020 | $294,000 | – | 13,873 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |